Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study

作者：Andrew L. Feldman, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Naoki Oishi, Guangzhen Hu, Pedro Farinha, Catalina Amador, Elı́as Campo, Wing C. Chan, James R. Cook, Jan Delabie, Kai Fu, Timothy C. Greiner, Laura K. Hilton, Giorgio Inghirami, Javeed Iqbal, Elaine S. Jaffe, Ryan D. Morin, Sarah L. Ondrejka, G. Ott, Stefania Pittaluga, Philipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Graham W. Slack, Susan L. Slager, Joo Y. Song, George Wright, Hao‐Wei Wang, Yu Zeng, Tadashi Yoshino, Xiaojun Wu, Ryan A. Wilcox, Xueju Wang, Min Shi, Akira Satou, Anamarija M. Perry, Roberto N. Miranda, L. Jeffrey Medeiros, Matthew J. Maurer, Eric Mou, Young Hyeh Ko, Kennosuke Karube, Brad S. Kahl, Liuyan Jiang, David L. Jaye, Alejandro A. Gru, Laurence de Leval, Weina Chen, Jennifer R. Chapman, James R. Cerhan, Carlos Barrionuevo, Stephen M. Ansell, Ahmed A. Aljudi · 发表于：Blood · 年份：2025 · DOI：10.1182/blood.2024027700 · 被引用次数：6 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Immune Cell Function and Interaction

ABSTRACT: Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non-tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-re...